Agent Information
The I-SPY Program is committed to open science, through timely publication and release of results, and ultimately data, from all arms of our trials.
SYD985 ([vic]-trastuzumab duocarmazine) is an antibody-drug conjugate that binds to HER2. It
consists of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody analog to trastuzumab (SYD977) attached by a cleavable linker (called SYD980), to the duocarmycin prodrug (seco-duocarmycin-hydroxybenzamide-azaindole or seco-DUBA or SYD978). Upon binding to HER2, the linker is leaved inside the tumor cell by proteases that release the active moiety, duocarmycin, which then binds to the minor groove of DNA, inducing apoptosis; trastuzumab also induces antibody-dependent, cell-mediated cytotoxicity against tumor cells that overexpress HER2.
Preclinical studies indicate SUYD985 is very active in HER2-positive breast cancer models, even those with lower HER2-expression.
Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.
